This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kominsky, S. L. Articles by Sukumar, S. Search for Related Content PubMed PubMed Citation Articles by Kominsky, S. L. Articles by Sukumar, S.

Clostridium perfringens Enterotoxin as a Novel-Targeted Therapeutic for Brain Metastasis

Departments of ¹ Orthopedic Surgery, ² Neurosurgery, and ³ Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland; ⁴ Department of Pathology, University of South Alabama College of Medicine, Mobile, Alabama; and ⁵ Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Requests for reprints: Scott Kominsky, Department of Orthopedic Surgery, 720 Rutland Avenue, Ross Building, Room 209, Johns Hopkins University School of Medicine, Baltimore, MD 21205. Phone: 410-502-6406; Fax: 410-502-6414; E-mail: kominsc{at}jhmi.edu.

Brain metastasis is the most commonly occurring intracranial tumor whose incidence seems to be increasing. With standard therapy, the average survival time of patients is 8 months, and treatment often leads to neurologic dysfunction in long-term survivors, emphasizing the need for novel therapeutics. Clostridium perfringens enterotoxin (CPE) has recently been shown to rapidly and specifically destroy cancer cells expressing CPE receptors claudin-3 and claudin-4. Unfortunately, the utility of CPE is precluded by systemic toxicity because its receptors are expressed in numerous organs. Here, we provide the first preclinical evidence that CPE may be uniquely suited to the local treatment of brain metastasis. By immunohistochemical analysis, claudin-3 and claudin-4 were expressed frequently in metastases from breast (15 of 18), lung (15 of 20), and colon (12 of 14) carcinoma, and infrequently in metastases from renal cell carcinoma (2 of 16) and melanoma (2 of 16). In contrast, expression of claudin-3 and claudin-4 was absent in adjacent normal brain tissue. Further examination of the central nervous system (CNS) revealed low or undetectable levels of claudin-3 and claudin-4 in all regions tested by Western and immunohistochemical analysis. Treatment of breast cancer cell lines (MCF-7, MDA-MB-468, NT2.5-luc) and normal human astrocytes with CPE in vitro resulted in rapid and dose-dependent cytolysis exclusively in breast cancer cells, correlating with claudin-3 and claudin-4 expression. Moreover, intracranial CPE treatment significantly inhibited tumor growth and increased survival in two murine models of breast cancer brain metastasis, without any apparent local or systemic toxicity. These data suggest that CPE therapy may have efficacy against a wide variety of brain metastases without CNS toxicity. [Cancer Res 2007;67(17):7977–82]

This article has been cited by other articles:

				L. Winkler, C. Gehring, A. Wenzel, S. L. Muller, C. Piehl, G. Krause, I. E. Blasig, and J. Piontek Molecular Determinants of the Interaction between Clostridium perfringens Enterotoxin Fragments and Claudin-3 J. Biol. Chem., July 10, 2009; 284(28): 18863 - 18872. [Abstract] [Full Text] [PDF]

				R. J. Mrsny, G. T. Brown, K. Gerner-Smidt, A. G. Buret, J. B. Meddings, C. Quan, M. Koval, and A. Nusrat A Key Claudin Extracellular Loop Domain is Critical for Epithelial Barrier Integrity Am. J. Pathol., April 1, 2008; 172(4): 905 - 915. [Abstract] [Full Text] [PDF]

				C. M. Van Itallie, L. Betts, J. G. Smedley III, B. A. McClane, and J. M. Anderson Structure of the Claudin-binding Domain of Clostridium perfringens Enterotoxin J. Biol. Chem., January 4, 2008; 283(1): 268 - 274. [Abstract] [Full Text] [PDF]